Introduction {#S1}
============

Alzheimer's disease (AD) is the most common form of dementia worldwide in older individuals, accounting for 60--80% of cases ([@B31]). It is widely reported that body shape (BS), generally acknowledged to be measured and reflected by anthropometric traits (ATs) such as body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-hip ratio adjusted for body mass index (WHRadjBMI), is associated with the development of several diseases ([@B46]; [@B35]).

Although there have been many conventional observational studies probing the influence of BS on the risk of AD, the reported results have been controversial. A meta-analysis based on prior systematic reviews provided a pooled relative risk estimate of 1.60 \[95% confidence interval (CI): 1.34, 1.92\] for BMI with AD, which was confirmed in a more recent meta-analysis of cohort studies ([@B1]; [@B28]). However, another prospective population-based study indicated that each unit increase in BMI was associated with an 8% decreased risk of dementia ([@B9]). A case-control study concluded that WC in older adults was significantly lower in the AD group than in the healthy cognition group, inconsistent with the findings of two cohort studies and another cross-sectional study ([@B30], [@B29]; [@B8]; [@B14]). Nevertheless, conventional studies could not identify whether these observed links are causal. Evidence that probes the causality between BS and AD is urgently needed to establish preventive measures.

Mendelian randomization (MR) analysis, which is a method based on instrumental variables (IVs), has been widely used to assess the potential causality between exposure and outcome. Two recent MR studies suggested high and low BMI were not the causal risk factors for AD, but were both limited by survivor bias and BS ([@B33]; [@B34]). Although [@B33] suggested that adiposity was not statistically associated with a risk of dementia and AD in sensitivity analyses, the effect of different BS on AD risk warrants further exploration. Therefore, we performed a large-scale MR analysis to assess the causal effect of BS on the risk of AD and simulation analyses to quantify the likely effect of BMI on risk of AD due to survivor bias.

Materials and Methods {#S2}
=====================

Study Design {#S2.SS1}
------------

Compared with conventional observational analyses, MR analyses could provide stronger evidence regarding causal inference ([Figure 1](#F1){ref-type="fig"}). MR analyses are analogous to randomized controlled trials (RCTs) and have been widely applied to investigate the potential causal relationship between exposure and the outcome variable. An individual's genotype at a signal nucleotide polymorphism (SNP) was randomized at conception. This process is almost identical to an individual randomized to receive treatment or not in a RCT; therefore, an SNP could be considered to be an IV in MR analysis ([@B12]; [@B17]). The study design of this MR analysis is mainly composed of the selection and validation of IVs, and the examination of causal effect between BS and risk of AD ([Figure 2](#F2){ref-type="fig"}).

![The explanation of Mendelian randomization analysis by a directed acyclic graph. The accuracy of estimating causality using Mendelian randomization (MR) analyses is based on the following three assumptions: (1) The instrumental variable (IV) associate robustly with the exposure (IV assumption 1). This assumption can be satisfied by ensuring *F* statistic \> 10 and that SNPs are selected using genome-wide significance levels (*P* \< 5 × 10^--8^), which suggests that potential bias from weak IV should not be substantial ([@B34]). (2) The IV is independent of combined influence of all confounders (IV assumption 2). For the same population and reference, we assess correlation of linkage disequilibrium between SNPs associated robustly with exposure and SNPs linked to possible known confounders. If the correlation coefficient is higher (i.e., *r*^2^ ≥ 0.5), the corresponding selected SNPs will be discarded ([@B12]). (3) The IV is independent of the outcome given the exposure and confounders (IV assumption 3). Horizontal pleiotropy, that IVs influence the outcome through alternative pathways other than the exposure, could violate this assumption. It can be checked by using MR-Egger regression and MR-PRESSO method ([@B35]; [@B43]).](fnins-13-01084-g001){#F1}

![Study design of two-sample Mendelian randomization analysis. In this MR analysis, exposure and outcome refer to body shape and Alzheimer's disease separately. MR, Mendelian randomization.](fnins-13-01084-g002){#F2}

Data Source {#S2.SS2}
-----------

Two-sample MR analyses were conducted using genome-wide association study (GWAS) summary data. The two datasets were required to have a population of homogeneous characteristics (similar genetic ancestry), and in this study all participants were of European descent. This research did not require the consent of each participant because individual-level data were not used.

The association of SNPs with ATs were obtained from 2015 summary data from the Genetic Investigation of Anthropometric Traits (GIANT) consortium ([@B27]; [@B39]). The dataset of associations of SNPs with BMI, WHR, WHRadjBMI, and WC includes a total of 2,554,637 SNPs in 322,154 individuals, 2,560,781 SNPs, 2,542,431 SNPs, and 2,565,407 SNPs in 210,088 individuals of European descent after imputation, respectively. The SNPs-AD dataset was from the stage I GWAS meta-analysis undertaken by the International Genomics of Alzheimer's Project (IGAP), including genotype-AD associations for 7,055,881 SNPs after imputation in 17,008 AD cases and 37,154 controls of European descent ([@B25]). However, sample overlap of the two datasets could bias the estimated causal effect. GWAS summary data contain meta-analyses of many larger and independent population-based cohorts; thus, the same cohort may be included in the SNPs-exposure and SNPs-outcome datasets simultaneously, i.e., sample overlap ([@B17]). As a result, we estimated the degree of sample overlap between the SNPs-each AT GWAS dataset and the SNPs-AD study ([Table 1](#T1){ref-type="table"}). In addition, strong IVs (i.e., *F* statistic far greater than 10) could reduce bias from sample overlap.

###### 

Possible sample overlap between the SNPs-each anthropometric trait and SNPs-Alzheimer's disease datasets.

  **Cohorts**                                                               **Number of participants**                                 
  ------------------------------------------------------------------------- ---------------------------- --------- --------- --------- ---------
  AGES-RS                                                                   2772                         3207      0         0         0
  CHS                                                                       2255                         3228      0         0         0
  FHS                                                                       3344                         8904      0         0         0
  KORA F4                                                                   434                          1811      0         0         0
  Sum                                                                       8795                         17150     0         0         0
  Total European participants                                               54162                        322,154   210,088   210,088   210,088
  Proportion of participants of overlapping cohorts in total participants   16.24%                       5.32%     0.00%     0.00%     0.00%

AD, Alzheimer's disease; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; WHRadjBMI, waist-to-hip ratio adjusted for body mass index.

Furthermore, the data in the two datasets for each SNP involved effect and other alleles, allele frequency of effect allele, beta-coefficient (SNPs-AD dataset: log-odds ratio \[log-OR\] of AD), standard error, and *P*-value, as well as corresponding chromosome and position.

The Selection and Validation of Instrumental Variables {#S2.SS3}
------------------------------------------------------

Instrumental Variables selected for exposure should be independent of each other, because linkage disequilibrium (LD) would introduce bias and lead to over-precise estimates in subsequent analysis, which could be ensured by clumping a large number of variants to a set of index SNPs ([@B35]). Index SNPs were obtained by clumping all SNPs based on LD (*R*^2^ threshold of 0.001) or the physical distance threshold of 10,000 kb, while the robust associations between index SNPs and each AT reached genome-wide significance level (i.e., *P* \< 5 × 10^--8^). After clumping, partial index SNPs were selected as IVs according to the following filtering conditions. First, the causal effects of BS on AD risk may be obscured by some known possible confounders; thus, the correlation coefficient (*r*^2^) between SNPs related to these confounders (i.e., Bonferroni-corrected *P* \< 5 × 10^--8^) and IVs should be less than 0.5 ([@B26]). Second, it is widely acknowledged that three major alleles of apolipoprotein E (*APOE* ε2/ε3/ε4) are the most significant known genetic factors for AD in various ethnic groups, determined by rs429358 and rs7412 sites that should be irrelevant to IVs ([@B41]). Index SNPs mismatching the above conditions were discarded and the remaining were selected as IVs. Furthermore, the statistical association between IVs and each AT was assessed using the *F* statistic, the calculation of which is detailed in the [Supplementary Methods](#SM1){ref-type="supplementary-material"}. The sub-dataset of IVs-each AT was then extracted and harmonized with the SNPs-AD dataset to obtain the corresponding IVs-each AT-AD dataset. However, some palindromic and ambiguous SNPs existed in the harmonized dataset and some SNPs selected from the AT dataset mismatched the AD dataset. Thus, these inappropriate SNPs were discarded and corresponding proxy SNPs were found. Suitable proxy SNPs must be in high LD with the inappropriate SNPs (*R*^2^ \> 0.9), and irrelevant to SNPs that may have been associated with possible confounders and the *APOE* gene.

Two-Sample Mendelian Randomization Analyses {#S2.SS4}
-------------------------------------------

For a single SNP, the Wald ratio is commonly used to derive the causal estimate ([@B42]; [@B16]). For multiple SNPs, inverse-variance weighted (IVW) linear regression, MR-egger regression, weighted-median method, and weighted-mode method were applied to obtain the overall causal estimate. Detailed descriptions of these methods are provided in the [Supplementary Methods](#SM1){ref-type="supplementary-material"}.

The two-sample analysis was performed as follows. First, the pooled causal estimates for multiple IVs were calculated only using the IVW and MR-egger methods ([@B5]; [@B3]). Diagnostic and sensitivity analyses were the implemented, after which there was no evidence of heterogeneity or horizontal pleiotropy. Second, four overall causal estimates for multiple IVs were separately derived. The MR analyses using MR-egger regression, weighted-median method, and weighted-mode method were regarded as sensitivity analyses to improve the reliability of the causal inference from the IVW method ([@B2]; [@B15]). Third, the OR (95% CI) for risk of AD per 1-SD increase in each AT was reported because interpretation is easier using this metric than an arbitrary difference, while 1-SD increment separately represents a 4.69 kg/m^2^ increase in BMI, 0.14 cm/cm increase in WHR, 0.08 units increase in WHRadjBMI, and 12.06 cm increase in WC ([@B12]).

Additional Analyses {#S2.SS5}
-------------------

These analyses were optional. When selecting IVs, partial index SNPs were removed because of the associations between them and potentially possible confounders. However, if these confounders were no longer regarded as confounders based on the results of the above MR analyses, the excluded SNPs were reconsidered as IVs. The MR analyses of BS and AD were conducted again to obtain more reliable results.

Sensitivity Analyses {#S2.SS6}
--------------------

Diagnostic and sensitivity analyses were performed to identify different violations of assumptions and included tests of heterogeneity and horizontal pleiotropy, as well as four diagnostic plots. Heterogeneity statistics, including Cochran's *Q*, *I*^2^, and *H* statistic, assessed heterogeneity in causal estimates from the IVW method ([@B19]; [@B18]). A *P*-value of Cochran's *Q* or *H* statistic less than 0.05 indicated heterogeneity in causal effects amongst all SNPs, while *I*^2^ values of 25, 50, and 75%, respectively, represent low, moderate, and high heterogeneity ([@B18]). Test of horizontal pleiotropy was conducted using MR-egger regression and a Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) approach. A non-zero intercept of the MR-egger regression suggested horizontal pleiotropy. In addition, the horizontal pleiotropic outliers that were identified using MR-PRESSO, along with outliers that were detected in a leave-one-out analysis, were removed ([@B43]). Moreover, phenome-wide association studies (Phewas) were used to interpret outliers and explore the potential reason why the IV assumptions were violated ([@B11]; [@B17]). Four diagnostic plots, including a scatter plot, forest plot, leave-one-out plot, and funnel plot, were applied to present the findings of the MR analysis of BS and AD and aid in detecting horizontal pleiotropy and heterogeneity. Further detailed descriptions are given in the [Supplementary Methods](#SM1){ref-type="supplementary-material"}.

Power Calculation {#S2.SS7}
-----------------

Statistical power is usually limited in MR analyses because of the lower variation in exposure explained by IVs and limited sample sizes, which could be computed using a published calculator ([@B4]; [@B22]).

Survivor Bias {#S2.SS8}
-------------

Bias from selective mortality should be considered in epidemiological studies, especially in degenerative neurosis. In this MR analysis, BMI and age are widely acknowledged to be related to mortality, which may lead to a survivor bias and invalid causal estimate to some extent ([@B32]). Both low and high BMI are unfavorable to individual survival, and age is positively related to mortality; based on this, a simulation for quantifying the likely effect of survivor bias on the causal estimate was performed, assuming no association between BMI and AD. If the effect of BMI on AD risk due to a survivor bias reaches a significance level of 0.05, the real causal estimate is biased toward the null, i.e., BMI may be associated with AD. Otherwise, the real causal estimate is not influenced. Large sample sizes (*n* = 500,000) were generated in this simulation, along with data on BMI values, age, IVs, alive/dead status, and AD status for each individual ([@B10]; [@B36]; [@B23]; [@B25]).

This simulation was performed as follows ([@B35]):

1.  Each individual was randomly assigned alleles at 60 instrumental SNPs based on corresponding real population-based allele frequencies. In other words, the genotype value of each SNP for each individual was generated and expressed as *g~*ij*~*, which represents the genotype value of SNP *j* (*j* = 1, 2, 3, ..., 60) for individual *i* (*i* = 1, 2, 3, ..., 500,000).

2.  Based on the created genotype values, the BMI value of each individual was generated as a function of allele frequencies of 60 instrumental SNPs and the beta coefficients of SNPs-BMI effects, plus a random number to obtain an individual difference, i.e., the BMI value of each individual could be simulated as follow: *x*~*i*~ = ∑*g*~*ij*~β~*j*~ + *e*~*j*~, where *e*~*j*~ followed a normal distribution with a mean of zero, and standard deviation of V~*E*~, where V~*E*~ was the residual phenotypic variance of BMI.

3.  We simulated the age for each individual through matching the age distribution reported in the AD meta-analysis ([@B25]).

4.  The alive/dead status for each individual was modeled as a function of the age and BMI value of this individual. Age-related mortality as baseline mortality was generated from the Gompertz--Makeham law of mortality, based on parameters determined by previous studies. The baseline survival function was the obtained, with which the effect of BMI on survival was incorporated to acquire an age- and BMI-related survival function. According to this full survival model, the alive/dead status of individuals was simulated ([@B10]; [@B23]).

The cumulative distribution function of Gompertz--Makeham law of mortality is referred to as the Gompertz--Makeham distribution and can be described as follows:
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The baseline survival function is derived through Gompertz--Makeham distribution and is as follows:
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The full survival model is*S*(*t*) = *S*~*b*~(*t*)*w*(*x*), where *w*(*x*) is a function of the impact of BMI on mortality.

5.  The AD status of individuals was generated according to the age-specific prevalence of AD obtained from a previously published study ([@B36]). This simulation assumed that AD status was exclusively related to age and independent of BMI values.

6.  Two subsets were selected for further analysis. All individuals in the first subset were simulated without any death, thus all the analyses for this subset should be immune to the survivor bias. The second subset of AD cases and controls involved individuals who were confirmed as alive based on the full survival model. The observational studies and MR analyses were performed on the two subsets, respectively.

7.  The complete process was repeated 1000 times to produce two distributions of BMI-AD effects separately from the baseline and full survival models. The two distributions were compared to assess the degree to which the effect of BMI on AD could be driven by a survivor bias.

Software and Packages {#S2.SS9}
---------------------

All analyses were conducted using R software (version 3.5.1). Based on a reference dataset of EUR population (1000 Genomes Project), the clumping procedure was implemented using R packages "Two-Sample MR" and "MRInstruments," and the procedure of looking for proxy SNPs was conducted using R package "proxysnp." The two-sample MR analysis was performed using R packages "Two-SampleMR," "MRPRESSO," and "Mendelian Randomization."

Results {#S3}
=======

The Selection and Validation of Instrumental Variables {#S3.SS1}
------------------------------------------------------

There were 69, 29, 38, and 42 index SNPs after clumping SNPs that, respectively, related to BMI, WHR, WHRadjBMI, and WC separately. Five of 69 index SNPs that were correlated with WHR-associated SNPs, while six of 29, none of 38, and 30 of 42 index SNPs that were correlated with BMI-associated SNPs were removed. None of the index SNPs correlated with the *APOE* gene. Additionally, some palindromic SNPs and mismatched SNPs were presented in the harmonized datasets, which were discarded and replaced by suitable proxy SNPs ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). Together 62 and 65 index SNPs for BMI, 23 and 29 index SNPs for WHR, and 12 and 41 index SNPs for WC remained in the first MR analysis and additional analysis, respectively, with 36 index SNPs for WHRadjBMI in the MR analysis. All *F* statistics showed far more than 10, which suggest it was unlikely for bias from weak instrument ([Table 2](#T2){ref-type="table"}). Therefore, these index SNPs were chosen as IVs for further MR analyses.

###### 

The validation of instrumental variables.

  **AT**      **The first analyses**   **Additional analyses**                         
  ----------- ------------------------ ------------------------- -------- ---- ------- --------
  BMI         62                       1.66%                     92.30    65   2.14%   114.17
  WHR         23                       0.59%                     88.14    29   0.77%   91.71
  WC          12                       0.23%                     65.54    41   1.42%   119.18
  WHRadjBMI   36                       1.13%                     108.16                

Remaining SNPs refer to the partial index SNPs after harmonizing the index SNPs-each AT dataset and the SNPs-Alzheimer's disease dataset. AT, Anthropometric trait; BMI, body mass index; WHR, waist-to-hip ratio; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; WC, waist circumference.

The First Mendelian Randomization Analyses {#S3.SS2}
------------------------------------------

In the MR analysis of BS and AD, the overall causal estimate from IVW method suggested no effect on risk of AD per SD change in each AT, which was the same as the results obtained using the other three methods comprising the MR-egger, weighted-mean, and weighted-mode methods ([Figure 3](#F3){ref-type="fig"}). The OR (95% CI) of BMI, WHR, WHRadjBMI, and WC with respect to AD from IVW methods separately using 60, 23, 36, and 12 IVs was 1.10 (0.90, 1.34) (*P* = 0.336), 1.05 (0.76, 1.45) (*P* = 0.761), 1.12 (0.89, 1.41) (*P* = 0.324), and 0.97 (0.59, 1.61) (*P* = 0.917).

![The overall causal effect of body shape on the risk of Alzheimer's disease from each of four different methods (inverse-variance weighted method, MR-egger regression method, weighted-median method and weighted-mode method). Results were reported as the odd ratio (OR) of AD per 1-SD increase in each anthropometric trait. The results of additional MR analyses were the more reliable causal estimates of ATs on AD, and the causal effect of WHRadjBMI on AD was displayed in this column was just for easy reading. MR, Mendelian randomization; AD, Alzheimer's disease; AT, anthropometric traits; BMI, body mass index; OR, odds ratio; WC, waist circumference; WHR, waist-to-hip ratio, WHRadjBMI, waist-to-hip ratio adjusted for body mass index.](fnins-13-01084-g003){#F3}

Additional Mendelian Randomization Analyses {#S3.SS3}
-------------------------------------------

We conducted additional MR analyses as BMI and WHR were no longer considered confounders based on the results of the first MR analyses. The overall causal estimate \[OR (95% CI)\] for the effect of a 1-SD increase in BMI on the risk of AD using 65 IVs in the IVW method was 1.04 (0.88, 1.23) (*P* = 0.652), and for the effect of per 1-SD increase in WHR on the risk of AD using 29 IVs was 1.01 (0.77, 1.33) (*P* = 0.930). Moreover, there were 38 IVs remaining for WC after sensitivity analyses, which explained 1.33% of the variance in WC and the corresponding *F* statistic was 120.97. The OR (95% CI) of AD per 1-SD increase in WC calculated using the IVW method was 1.02 (0.82, 1.27) (*P* = 0.836). All the above results were in accordance with the conclusions of the other three methods ([Figure 3](#F3){ref-type="fig"}).

Power Calculation {#S3.SS4}
-----------------

We had sufficient statistical power to identify the moderate causal effect of BS on AD risk ([Table 3](#T3){ref-type="table"}).

###### 

Statistical power in Mendelian randomization analyses of body shape and the risk of Alzheimer's disease.

  **Each AT**                                 ***R*^2^**   **Statistical power**   **Minimal/Maximal detectable OR**
  ------------------------------------------- ------------ ----------------------- -----------------------------------
  **BMI**                                                                          
  Positive/negative correlated with AD risk   2.14%        81%                     1.19/0.83
  Previous association ([@B37])               2.14%        \>99%                   1.80^∗^
  **WHR**                                                                          
  Positive/negative correlated with AD risk   0.77%        80%                     1.33/0.73
  Previous association ([@B37])               0.77%        \>99%                   2.00^∗^
  **WHRadjBMI**                                                                    
  Positive/negative correlated with AD risk   1.13%        82%                     1.27/0.77
  **WC**                                                                           
  Positive/negative correlated with AD risk   1.33%        80%                     1.24/0.79

Based on our sample size (case/control: 17,008/37,154, total: 54,162), minimal/maximal detectable odds ratio (OR) was calculated at a significance level of 0.05.

R

2

refers to the proportion of variance explained by IVs in each anthropometric trait. The statistical power of previous association in each AT means the power to detect previous association in this MR analysis. AD, Alzheimer's disease; AT, anthropometric traits; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; WHRadjBMI, waist-to-hip ratio adjusted for body mass index.

∗

Association provided by a previous observational study.

Sensitivity Analyses {#S3.SS5}
--------------------

Finally, 65 IVs for BMI, 29 IVs for WHR, 36 IVs for WHRadjBMI and 38 IVs for WC were identified ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}). For BMI, WHR, WHRadjBMI, and WC, the *I*^2^ value was 21.86, 20.46, 18.73, and 24.90%, respectively, while the *P*-value of the MR-PRESSO global test was 0.0674, 0.1688, 0.1577, and 0.0833, respectively. Sensitivity analyses of the first and additional MR analyses were implemented, and the estimates of causal effects were under the condition of no evidence of heterogeneity and horizontal pleiotropy ([Supplementary Table S3](#SM1){ref-type="supplementary-material"} and [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}).

Simulation Analyses of Survivor Bias {#S3.SS6}
------------------------------------

The simulation to assess the likely effect of survivor bias demonstrated no evidence that the causal estimate obtained using the IVW method was driven by survivor bias in the MR analysis of BMI and AD. Based on the results of observational studies and the MR analyses of the simulated dataset, the mean estimated causal effects and distribution of effects in the presence of survivor bias were similar to those without survivor bias, which both obeyed a Gaussian distribution. In conclusion, the result of the MR analysis using the IVW method compared with that using the MR-Egger method was more robust to bias from selected mortality ([Figure 4](#F4){ref-type="fig"} and [Supplementary Figure S2](#SM1){ref-type="supplementary-material"}).

![Survivor bias. The causal effects of these simulation analyses were obtained separately from base survivor model and full survivor model using observational study, inverse-variance weighted method and MR-egger method. Each point and horizontal line denote the mean estimated causal effect and 95% confidence interval (CI) from corresponding model and method. AD, Alzheimer's disease; BMI, body mass index; baseline, baseline survivor model without survivor bias; full, full survivor model with selected mortality.](fnins-13-01084-g004){#F4}

Discussion {#S4}
==========

Mendelian randomization analyses findings in this study suggested that BS has no influence on the risk of AD. To the best of our knowledge, there have been two MR studies of BMI and AD, which were limited by the possible influence from survivor bias and BS ([@B33]; [@B34]). [@B33] reported the non-significance of the relationship between adiposity and AD by using mechanism-specific polygenic scores as IVs; however, their sensitivity analysis could not explore the influence of different BS on the risk of AD. This study of BMI and AD used large sample sizes to implement the MR analysis and simulation to explain the influence of survivor bias on the causal effect, with an MR analysis of WHRadjBMI being conducted, which demonstrated again that a causal effect of BMI on risk of AD, independent of survivor bias and BS, was not present. Additionally, to the best of our knowledge, this is the first MR analysis to explore the causal effect of BS on AD and no evidence of an effect was found.

Associations observed in available conventional epidemiologic evidence between BS and AD remained controversial ([Supplementary Table S4](#SM1){ref-type="supplementary-material"}). These observational studies defined an AT as a discrete or continuous variable and applied different methods to perform analyses, together with a study-specific bias, which contributed to the heterogeneity of the results. A follow-up study and cohort study indicated that low BMI was a risk factor of AD, whereas one case-control study found a U-shaped association ([@B37]; [@B20]; [@B34]). Three cohort studies investigated the influence of BMI as a continuous variable on AD, two of which supported our results, and the other reported a positive correlation between them ([@B30]; [@B29]; [@B24]). Some studies proposed that lower BMI was linked with lower blood pressure, which mitigated the risk of AD, because hypertension could cause dysfunction of blood brain-barrier (BBB) via the formation of free oxygen radicals ([@B38]; [@B34]). Other interpretations of the U-shaped association were that lower BMI was related to a higher risk of AD because of reverse causation or it was a predictor of preclinical AD, and associations of higher BMI with an elevated risk of AD could be considered as evidence that obesity was related to a greater risk of AD ([@B30], [@B29]). Moreover, two cohort studies showed a clear positive association between WHR as a continuous variable and risk of AD, contrary to the conclusions drawn by a case-control study ([@B37]; [@B38]; [@B29]). Two cohort studies concluded there was no association between WC and risk of AD ([@B30], [@B29]). Another observational study that performed multivariate analyses suggested that low BMI and WC were pre-clinical markers of AD ([@B8]).

We investigated the potential causal relationship between commonly used BS-related indexes, including BMI, WHR, WHRadjBMI, WC, and AD, and concluded that BS may play no causal role in AD. Regarding the relationship between obesity and AD, we further selected 18 obesity-related SNPs from 65 BMI-related SNPs as IVs to perform an MR analysis of obesity and AD, which explained 8.33% of the variance in obesity and the corresponding *F* statistic was 498.12. The ORs (95% CI) for AD per 1-SD increase in obesity calculated using the IVW method, MR-Egger method, weighted-median method, and weighted-mode method were, respectively, 0.97 (0.89, 1.04) (*P* = 0.387), 0.96 (0.77, 1.20) (*P* = 0.728), 1.00 (0.89, 1.12) (*P* = 0.974), and 1.02 (0.88, 1.17) (*P* = 0.824) separately. However, such findings together with the negative association of BMI and WHRadjBMI with AD ([Figure 3](#F3){ref-type="fig"}) do not allow us to definitely conclude that obesity has no causal relationship with AD, which is often difficult to clarify. In fact, there often exist different pathways linking SNPs, obesity, and AD. Furthermore, it may be challenging to construct a reasonable counterfactual and causal inference model. Overall, exploring the real causal association and underlying mechanism between obesity and a disease such as AD is a challenging issue. Some explanations have been suggested and need to be examined in the future. Adiposity is closely related to stroke and vascular risk factors, such as hypertension, which could affect the deposition of amyloid β (Aβ), alter brain structure, and enhance BBB permeability. Meanwhile, many cytokines secreted by adipose tissue penetrate the BBB to influence normal brain function and thereby increase the risk of AD ([@B29]; [@B34]). The association between AD and abdominal obesity was supported by a study that proposed higher WHR could affect brain normal structures and functionality through neurodegenerative, vascular, or metabolic processes ([@B21]). However, this mechanism was thought to be unclear and partially explained by insulin resistance ([@B37]). Insulin resistance is always accompanied by type 2 diabetes and hyperinsulinemia. Diabetes may be related to AD through mediating oxidative stress and protein glycosylation ([@B32]); however, peripheral insulin could directly damage normal brain structures and functionality by crossing the BBB to act on insulin receptors located in the central nervous system (CNS). Insulin plays an important role in the up-regulation of extracellular Aβ levels and phosphorylation of tau protein, which could accelerate the process of AD ([@B32]). Another one study showed lower serum insulin-like growth factor-1 (IGF-1) levels were a risk factor for AD whereas higher IGF-1 levels could protect individuals against AD at the subclinical and clinical stages ([@B44]). The evidence from conventional epidemiological studies regarding the effects of peripheral insulin and IGF-1 levels on the risk of AD has been weak and conflicting. Experimental findings showed that altered peripheral blood levels of insulin or IGF-1 were irrelevant to the normal functionality of the CNS, but insulin or IGF-1 locally produced in the CNS played a more important role in regulating CNS neuronal functions, corresponding with the consistent result of a recent two-sample MR analysis ([@B40]; [@B45]).

This study has several strengths. First, avoiding reverse causation, a large sample size, and sufficient statistical power were ensured in this two-summary data MR design to identify a causal reference. Second, various methods including IVW, MR-egger, weighted-median, and weighted-mode method were applied in the MR analyses, the causal estimates of which were consistent, thus increasing the robustness of our findings. Third, the influence of confounding factors on the causal estimate was weakened to some extent over the strict selection of IVs. For each AT and AD, the results from two MR analyses were consistent with each other, showing no evidence of a causal effect of BS on AD risk. The *APOE* gene that plays an important role in modulating the deposition of Aβ and neurofibrillary tangles of AD is the most common genetic cause of AD and was not in LD with any IVs ([@B13]). Fourth, the MR-egger regression and MR-PRESSO methods were both used to check the possible horizontal pleiotropy and identify outliers. Furthermore, the source of horizontal pleiotropy could be detected through the Phewas of outliers. Fifth, our MR analyses of BS and AD risk had sufficient statistical power to detect moderate causal effects as noted in observational studies. However, there are several limitations. First, the two-sample MR summary data analysis assumed a linear relationship between each AT and AD. Indeed, a U- or J-shaped association between each AT and related disease is common in observational studies ([@B7]). A non-linear causal effect warrants other methods that need individual level data ([@B6]). Second, it was impossible to compare the difference in the causal estimates in subgroups using summary data. Third, [Table 1](#T1){ref-type="table"} shows that there was a minimal proportion of sample overlap in this study, the influence of which could be minimized by using strong IVs. Finally, reasonable biological interpretations for the results of the MR analyses were not provided. Therefore, the results from these MR analyses could not be considered as a definite answer and should be generalized to the rest of the population with caution.

Conclusion {#S5}
==========

In conclusion, the evidence from MR analyses showed no causal effect of BS on AD risk. An RCT is not feasible; hence, experimental findings from biological mechanisms are expected to provide a reasonable interpretation for these results. It is plausible and recommended that our findings are replicated in other MR studies with individual-level genotyping data and in other ethnic groups. Although BS is not associated with AD risk based on our results, maintaining body weight in the normal range is beneficial.
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A β

:   Amyloid β

AD

:   Alzheimer's disease

APOE

:   apolipoprotein E

AT

:   anthropometric trait

BBB

:   blood brain-barrier

BMI

:   body mass index

BS

:   body shape

CI

:   confidence interval

CNS

:   central nervous system

GIANT

:   Genetic Investigation of Anthropometric Traits

GWAS

:   genome-wide association study

IAGP

:   International Genomics of Alzheimer's Project

IGF-1

:   insulin-like growth factor-1

IV

:   instrumental variable

IVW

:   inverse-variance weighted

LD

:   linkage disequilibrium

MR

:   Mendelian randomization

OR

:   odds ratio

Phewas

:   phenome-wide association studies

RCT

:   randomized controlled trial

SNP

:   signal nucleotide polymorphism

WC

:   waist circumference

WHR

:   waist-to-hip ratio

WHRadjBMI

:   waist-to-hip ratio adjusted for body mass index.
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